TeamDrive
RUS

Viewpoint: Regulators Hinder Process Innovation

06 September 2018

BioPrarm International

Regulators are creating inertia in pharmaceutical manufacturing practices by dictating approaches to innovation, says Girish Malhotra, president of EPCOT International; however, shorter approval times and financial incentives can encourage innovation.

In an article he authored in the first part of the sixth CPhI Annual Report, Malhotra warned regulators will induce “innovation inertia”’ without a change of philosophy. “The problem we have presently is that, for manufacturing technology innovations to be successful, pharma companies (brand and generics) need to have an economic and commercial incentive. It is this incentive that drives forward innovation and advancement. But the regulators—in particular the FDA—are still dictating approaches to industry without asking what the commercial justifications are to support them,” writes Malhotra.

The cGMP practice guidelines essentially force a “cultural dogma”’ in pharma companies that aims to meet regulations rather than encourage to innovate, he writes. Valuable process advances may be lost if regulators continue to dictate approaches.

Contract manufacturers have strong economic incentives to innovate process and manufacturing improvements, he argues, and these organizations can play a role in promoting manufacturing innovation.

The CPhI Annual Report, which will include more than 10 expert contributions and the CPhI manufacturing and bio leagues tables, will be released at CPhI Worldwide, Oct. 9–11, 2018, in Madrid, Spain. CPhI Worldwide announced the first part of the report in an Aug. 23, 2018 press statement.

CPhI and Pharmaceutical Technology are UBM (part of Informa plc) brands.

Source


Previous publication Next publication

Media Center

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

  • 18 October 2018

    Russia emerges as frontrunner in global fight against tuberculosis

    Russia has turned out to be the world’s most successful tuberculosis fighter, Russian Health Minister Veronika Skvortsova stated  during the interview with the Rossiya-24 channel. "We are the global leader according to the pace in solving this issue," she noted, adding, "all countries acknowledge Russia’s foremost role here."

  • 17 October 2018

    Scientists developed new tool for open exchange of biomaterials

    A new easy-to-use legal tool that enables open exchange of biological materials was launched. The OpenMTA is a Material Transfer Agreement (MTA) designed to support openness, sharing and innovation in global biotechnology. Material Transfer Agreements (MTAs) provide the legal frameworks within which research organisations define terms and conditions for sharing their materials – everything from DNA molecules to plant seeds to patient samples.

  • 16 October 2018

    The First FDA-approved Digital Pill — What It Means for Pharma

    Last year, the U.S. Food and Drug Administration (FDA) approved what is perhaps the boldest use of digital technology in healthcare: a pill that is integrated with an ingestible sensor that captures information about whether the patient has complied with her medication regimen. A patient ingests the pill and it sends the data to a patch worn on her torso, which adds various physiologic measures. From there the information is wirelessly sent to a mobile phone app, allowing both the patient and her physician to track how the patient is using and responding to her medication.

Read more